Inosine Fails to Slow Early Parkinson Disease Progression in Phase 3 Trial
Researchers assessed the impact of oral inosine, a metabolic precursor of urate, on disease progression in patients with early Parkinson disease.
Parkinson Disease
Study Identifies New Genes Tied to Higher Risk for Parkinson Disease
Researchers sought to identify candidate casual genes for Parkinson disease by integrating the genome-wide association study results with large-scale expression quantitative trait loci in 13 brain tissues.
Predictors of Deep Brain Stimulation Efficacy for Impulsive and Compulsive Behavior in PD
Researchers sought to investigate clinical predictors of the effect of subthalamic nucleus-deep brain stimulation on impulsive and compulsive behaviors in patients with Parkinson disease.
Safety of Subcutaneous Levodopa Infusion in Parkinson Disease Over 1 Year
Researchers evaluated the 1-year safety data on subcutaneous levodopa/carbidopa continuous infusion with ND0612, an investigational subcutaneous delivery system providing minimally invasive continuous infusion, in patients with Parkinson disease.
Higher Ischemic Stroke Risk Among Patients With Parkinson Disease With LRRK2 Variations
At MDS 2021, researchers shared study results on the effect of Parkinson disease (PD)-related genes on the risk for cardiovascular events among patients with genetic forms of PD, including those with variations in the LRRK2 and GBA genes.
Device-Aided Therapies Improve Off-Time, Quality of Life in Advanced Parkinson Disease
In a systematic review and network meta-analysis presented at MDS 2021, researchers assessed the effect of device-aided strategies on off-time improvement and quality of life in Parkinson disease.
Patients With Parkinson Disease Hospitalized With COVID-19 May Have Higher Mortality
Researchers assessed the features of Parkinson disease (PD) pathophysiology that may increase the risk for COVID-19 mortality among hospitalized patients with PD.
Safety and Efficacy of Venglustat Assessed in GBA Gene Carriers With Parkinson Disease
In a poster presented at MDS 2021 and as part 2 of the MOVES-PD trial, researchers assessed the safety and efficacy of venglustat, a glucosylceramide synthase inhibitor, in patients stratified by GBA gene variation severity.
Specialized Light Therapy Improves Motor and Nonmotor Symptoms in Parkinson Disease
Researchers assessed the impact of specialized light therapy on motor and nonmotor symptoms in patients with Parkinson disease.
What Is the Effect of Parkinson Disease Medications on the Gut Microbiome?
Researchers observed the differences in gut microbiota composition between drug-naive and medically treated patients with Parkinson disease.
- Loading...
Loading...
Loading... 
Loading...